FILSPARI (Sparsentan) – IgAN | HongKong DengYue Medicine
- Generic Name/Brand Name: Sparsentan / FILSPARI®
- Indications: IgAN
- Dosage Form: Tablet
- Specification: 400 mg × 30 tablets/bottle
Sparsentan Application Scope
FILSPARI is a first-in-class, dual endothelin angiotensin receptor antagonist (DEARA). It blocks endothelin type A (ETA) and angiotensin II type 1 (AT1) receptors, reducing proteinuria and slowing kidney function decline in IgA nephropathy.
Indication:
-
Primary IgA nephropathy (IgAN): In adults at risk of rapid disease progression.

Sparsentan Characteristics
-
Ingredients: Active ingredient: Sparsentan
Excipients: microcrystalline cellulose, povidone, magnesium stearate, etc. -
Properties: Film-coated oral tablets.
-
Packaging Specification: 200 mg tablets, 90 tablets/bottle.
-
Storage: Store at 20–25°C. Protect from moisture.
-
Expiry Date: As indicated on package.
-
Executive Standard: FDA approval standard.
-
Approval Number: Per local authority.
-
Date of Revision: As indicated in insert.
-
Manufacturer: Travere Therapeutics, Inc.
Guidelines for the Use of FILSPARI
-
Dosage and Administration:
-
Recommended Dose: 400 mg orally once daily.
-
Administration: Swallow whole, with or without food.
-
Missed Dose: If a dose is missed, take as soon as remembered unless close to next dose. Do not double dose.
-
-
Adverse Reactions:
-
Common Adverse Reactions:
-
Peripheral edema
-
Hypotension, dizziness
-
Hyperkalemia
-
Anemia, fatigue
-
-
Serious Adverse Reactions:
-
Hepatotoxicity (elevated liver enzymes)
-
Embryo-fetal toxicity (contraindicated in pregnancy)
-
-
-
Contraindications:
-
Pregnancy (high teratogenic risk)
-
Hypersensitivity to sparsentan or excipients
-
-
Precautions:
-
Monitor liver function and serum potassium regularly
-
Teratogenic risk → use only under REMS program in the U.S.
-
Use with caution in patients with hypotension or renal impairment
-
Sparsentan Interactions
-
Avoid use with strong CYP3A inhibitors/inducers
-
Risk of hyperkalemia when combined with potassium-sparing diuretics or RAAS inhibitors
Note:
- If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
- This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.










Reviews
There are no reviews yet.